Rituximab Dosing and Administration Guidelines

Standard Dosing Regimens

The American College of Physicians recommends rituximab 1000 mg administered on days 1 and 15, or alternatively 375 mg/m² once weekly for 4 weeks, with follow-up monitoring including baseline immunoglobulin levels, hepatitis B and C screening, and latent tuberculosis screening prior to administration 1
For idiopathic inflammatory myopathies, the recommended dosing regimen is rituximab 1000 mg repeated on day 15, or 375 mg/m² once weekly for 4 weeks 1
For Waldenström's macroglobulinemia, rituximab 375 mg/m² weekly for 4 cycles is often combined with other agents, as recommended by the International Workshop on Waldenström's Macroglobulinemia 2, 3
For diffuse large B-cell lymphoma, the National Comprehensive Cancer Network recommends rituximab 375 mg/m² per cycle when combined with CHOP chemotherapy 4
For membranous nephropathy, two commonly used approaches are 2 bi-weekly doses of 1 g or 4 weekly doses of 375 mg/m², which appear to be clinically equivalent, according to the American Society of Nephrology 5

The Rituximab in Myositis study showed favorable response in 83% of patients with refractory disease throughout a 44-week trial, as reported by the Mayo Clinic 1
For adults with inflammatory myopathies, the American College of Rheumatology recommends administering two 1000 mg doses of rituximab 2 weeks apart 1
For Waldenström's macroglobulinemia, when combined with bortezomib, rituximab 375 mg/m² at each cycle during 4 cycles is recommended by the European Society for Medical Oncology 3
IgM flare is a common concern when initiating therapy for Waldenström's macroglobulinemia and should be monitored, as advised by the International Workshop on Waldenström's Macroglobulinemia 3

Baseline immunoglobulin levels (IgG, IgM, IgA) should be obtained, as recommended by the American College of Physicians 1
Hepatitis B and C antibody status should be determined, according to the Centers for Disease Control and Prevention 1
Latent tuberculosis screening should be performed prior to administering rituximab, as advised by the American Thoracic Society 1

Severe infectious complications are a concern, particularly in immunosuppressed patients, as reported by the Infectious Diseases Society of America 1
Progressive multifocal leukoencephalopathy has been reported in rheumatic patients treated with rituximab; use caution in immunosuppressed patients, as recommended by the American College of Rheumatology 1
Prophylaxis against herpes zoster is strongly recommended for patients receiving rituximab with proteasome inhibitors, as advised by the European Society for Medical Oncology 3
Avoid rituximab in patients with active hepatitis B infection due to risk of reactivation, as recommended by the American Association for the Study of Liver Diseases 4

Complete blood count with differential should be monitored at baseline and at 2-4 month intervals during treatment, as recommended by the National Comprehensive Cancer Network 7
Clinical response should be assessed through disease-specific parameters (e.g., muscle strength in myositis, IgM levels in Waldenström's), as advised by the American College of Physicians 1, 2
For lymphoma patients, FDG-PET/CT is the recommended standard for post-treatment assessment, according to the National Comprehensive Cancer Network 4